Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKE | Q14164 | 3/20 | 0.49 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.49 |
| ▸ | CDK2 | P24941 | 6/20 | 0.47 |
| ▸ | IGF1R | P08069 | 3/20 | 0.46 |
| ▸ | CDK4 | P11802 | 2/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 3/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3765120 | 0.93 | CDK2 (0.48) | IKBKETBK1CDK2IGF1RCDK4 | |
| SCHEMBL3761671 | 0.92 | CDK2 (0.48) | IKBKETBK1CDK2IGF1RCDK4 | |
| SCHEMBL3755303 | 0.86 | CDK2 (0.52) | IKBKETBK1CDK2CDK4CCNE1 | |
| SCHEMBL3766961 | 0.83 | CDK2 (0.52) | CDK2IGF1RCDK4CCNE1EGFR | |
| SCHEMBL3760297 | 0.83 | CDK2 (0.59) | CDK2IGF1RCDK4CCNE1KDR | |
| SCHEMBL3772463 | 0.78 | IGF1R (0.51) | IKBKETBK1IGF1REGFRBTK | |
| SCHEMBL3765211 | 0.77 | CAMK2D (0.61) | CDK2IGF1RCDK4CCNE1EGFR | |
| SCHEMBL3762659 | 0.76 | CDK2 (0.56) | CDK2IGF1RCDK4CCNE1KDR | |
| SCHEMBL3760568 | 0.76 | CDK2 (0.74) | CDK2IGF1RCDK4CCNE1EGFR | |
| SCHEMBL3766749 | 0.76 | CDK2 (0.53) | CDK2IGF1RCDK4CCNE1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | IKBKE 484/4885TBK1 1508/4885CDK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.